GHRS — GH Research PLC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1855129 ·
Last close
$23.15
Market Cap
$1.59B
52W High
$24.66
52W Low
$12.77
ADV30
272,258
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -18,748,000 | -18,967,000 | 275,267,000 | 242,652,000 | 11,890,000 |
| Dec 2025 | 0 | — | -16,699,000 | -14,137,000 | 288,230,000 | 246,251,000 | 8,527,000 |
| Sep 2025 | 0 | — | -16,535,000 | -14,020,000 | 302,022,000 | 249,654,000 | 10,625,000 |
| Jun 2025 | 0 | — | -14,691,000 | -9,289,000 | 313,428,000 | 253,873,000 | 10,249,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-43,552,000
Investing CF
$46,172,000
Financing CF
$139,651,000
CapEx
$-121,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.80
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-154,425,000
Inventory
—
Receivables
$1,295,000
ST Investments
$34,457,000
EBIT TTM
$-48,223,000
Pretax Income TTM
$-48,258,000
Interest Exp TTM
$35,000
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -60,676,000 | -48,258,000 | 288,230,000 | 8,527,000 | — | -43,552,000 |
| Dec 2024 | 0 | -50,246,000 | -38,961,000 | 188,273,000 | 9,322,000 | — | -42,285,000 |
| Dec 2023 | 0 | -41,221,000 | -35,587,000 | 226,300,000 | 7,332,000 | — | -33,336,000 |
| Dec 2022 | 0 | -30,675,000 | -22,456,000 | 254,362,000 | 4,546,000 | — | -26,199,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.00
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QURE | uniQure N.V. | $1.59B | $25.15 | — |
| DMRA | Damora Therapeutics, Inc. | $1.59B | $25.89 | — |
| ATAI | AtaiBeckley Inc. | $1.58B | $4.29 | — |
| ABCL | AbCellera Biologics Inc. | $1.62B | $5.29 | — |
| NUVB | Nuvation Bio Inc. | $1.63B | $4.69 | — |
News headlines (Yahoo Finance, 1h cache)
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-05-18 14:03 · Yahoo
Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans
2026-05-16 20:12 · Yahoo
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 11:00 · Yahoo
GH Research Announces Pricing of $117.5 Million Underwritten Offering
2026-04-29 12:00 · Yahoo
FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit.
2026-04-24 20:12 · Yahoo
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
2026-04-24 14:19 · Yahoo
‘Can I have some, please?’: Trump jokes as he signs psychedelics order after Joe Rogan push. These stocks soar
2026-04-22 12:49 · Yahoo
How Trump Sent Psychedelics-Tied Compass Pathways And Others Flying
2026-04-20 20:26 · Yahoo
Sector Update: Health Care Stocks Fall Late Afternoon
2026-04-20 19:55 · Yahoo
Market Feels Weak, But Stocks Tell Stories
2026-04-20 18:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.